Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630615 | 1.00 | HTR2C (0.36) | HTR2CHTR6RAD52 | |
| SCHEMBL3450910 | 0.98 | HTR2C (0.37) | HTR2CHTR6 | |
| SCHEMBL1241644 | 0.83 | RIPK1 (0.31) | — | |
| SCHEMBL508981 | 0.72 | HTR2C (0.39) | HTR2CHTR6RAD52 | |
| SCHEMBL19673865 | 0.72 | HTR2C (0.39) | HTR2CHTR6RAD52 | |
| SCHEMBL3594154 | 0.70 | — | — | |
| SCHEMBL10325516 | 0.70 | HTR6 (0.46) | HTR2CHTR6 | |
| SCHEMBL28752486 | 0.70 | HTR6 (0.38) | HTR2CHTR6 | |
| SCHEMBL3448296 | 0.70 | SLC6A1 (0.36) | HTR6 | |
| SCHEMBL2383924 | 0.69 | KDM4E (0.37) | HTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6251861-B1 | CYCLO(D-ASP-ASP(R1)-ASP-D-THG(2)-LEU-TRP) DISODIUM SALT, WHERE ASP(R1) IS AN ASPARTIC ACID BETA-4-PHENYLPIPERAZINE AMIDE RESIDUE AND THG(2) IS 2-(2-THIENYL)GLYCINE; ANTI-ENDOTHELIN ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1099690-A1 | MONOCYCLIC $g(b)-LACTAM COMPOUNDS AND CHYMASE INHIBITORS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2001-05-16 | — | — | EP | disclosed |
| EP-0815870-A2 | Composition for prohylaxis or treatment of cerebral infarction | Takeda Chemical Industries, Ltd. (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | HTR2C 3419/4885HTR6 1305/4885RAD52 4773/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | HTR2C 3419/4885HTR6 1305/4885RAD52 4773/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | HTR2C 2049/4885HTR6 4311/4885RAD52 1105/4885 |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | HTR2C 1983/4885HTR6 405/4885RAD52 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.